QLT, Sanofi Settle Patent Dispute With TAP Over Prostate Cancer Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
TAP receives combined $157.5 million to end patent conflict between TAP’s Lupron Depot and QLT/Sanofi-Aventis’ Eligard.
You may also be interested in...
Eligard Temporary Suspension Looms Following Permanent Injunction
QLT is seeking a stay to keep its prostate cancer therapy on the market pending the appeal it plans to file in federal appeals court.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Exec discusses the firm’s pulmonary arterial hypertension drug Tracleer and other endothelin receptor antagonists in Actelion’s pipeline.